Kathleen M. Loomes, Robert H. Squires, Deirdre Kelly, Sanjay Rajwal, Nisreen Soufi, Alain Lachaux, Irena Jankowska, Cara Mack, Kenneth D. R. Setchell, Palaniswamy Karthikeyan, Ciara Kennedy, Alejandro Dorenbaum, Nirav K. Desai, Will Garner, Thomas Jaecklin, Pamela Vig, Alexander Miethke, Richard J.
Xingyu Lv, Jiang Chen, Jiayan He, Lidan Hou, Yiyue Ren, Xiaoyun Shen, Yifan Wang, Tong Ji, Xiujun Cai – 3 May 2022 – Pyroptosis is a kind of programmed cell death primarily mediated by gasdermin D (GSDMD) and shown to regulate multiple diseases. However, its contribution to liver regeneration, a fine‐tuned tissue repair process mediated primarily by hepatocytes after mass loss, remains unclear. Herein, we found that caspase‐11/GSDMD‐mediated pyroptosis was activated in regenerating liver after 70% partial hepatectomy.
Benjamin L. Shneider, Binita M. Kamath, John C. Magee, Nathan P. Goodrich, Kathleen M. Loomes, Wen Ye, Cathie Spino, Estella M. Alonso, Jean P. Molleston, Jorge A. Bezerra, Kasper S. Wang, Saul J. Karpen, Simon P. Horslen, Stephen L. Guthery, Philip Rosenthal, Robert H. Squires, Ronald J. Sokol, for the Childhood Liver Disease Research Network (ChiLDReN) – 3 May 2022 – The conduct of long‐term conventional randomized clinical trials in rare diseases is very difficult, making evidenced‐based drug development problematic.
Natali S. Sobel Naveh, Emily M. Traxler, Kelly A. Duffy, Jennifer M. Kalish – 3 May 2022 – Beckwith‐Wiedemann Syndrome (BWS) is the most common human overgrowth disorder caused by structural and epigenetic changes to chromosome 11p15. Patients with BWS are predisposed to developing hepatoblastoma (HB). To better understand the mechanism of HB oncogenesis in this cancer predisposition background, we performed the first multi‐dimensional study of HB samples collected from patients diagnosed with BWS.
AASLD endeavors to create and support a culture of diversity, equity, and inclusion within the association and all aspects of the hepatology continuum.
AASLD is a global association committed to connecting scientists, physicians, surgeons and other health care providers interested in liver disease around the world.
Public policy issues having a direct impact on the discipline are actively monitored and communicated by the Public Policy Committee, which is making recommendations to influence issues as they are raised in the nation's capital.
The American Association for the Study of Liver Diseases is the leading organization of scientists and health care professionals committed to preventing and curing liver disease.
Grace L. Su, MD, FAASLD is the H. Marvin Pollard Collegiate Professor of Gastroenterology III and Professor of Medicine and Surgery at the University of Michigan Medical School. After completing her undergraduate degree from Yale University and M.D. from the University of Chicago, she pursued her residency and fellowship at the University of Pittsburgh.
As a physician scientist, Dr. Su has a long history of performing clinical and translational research in the area of chronic liver disease and cirrhosis. She is Director of the Morphomics Analysis Group at the University of Michigan, a multidisciplinary collaborative of physicians, biostatisticians and engineers developing methods for analyzing medical imaging. Their work has evolved into analytic morphomics, an innovative high-throughput, highly automated, anatomically indexed platform that measures body composition and organ condition. By linking imaging features to clinical outcomes, they have been able develop highly accurate non-invasive methods for the diagnosis and prognosis of patients with liver disease as well as hepatocellular carcinoma (HCC).
Disclosures of Potential Conflicts of Interest
Dr. Su has nothing to disclose.
W. Ray Kim, MD, MBA, FAASLD, Professor of Medicine at Mayo Clinic Arizona, Scottsdale, AZ
Dr. Kim received his MD degree from Seoul National University and his MBA from the University of Pennsylvania. Following his medicine residency at Seoul National University and the University of Arkansas, he underwent gastroenterology and hepatology fellowship training at Mayo Clinic in Minnesota. Subsequently, Ray joined the faculty of the Mayo College of Medicine, where he established his research in prognostication in patients with chronic liver disease. He is best known for his work in developing, validating and refining the Model for End-stage Liver Disease (MELD) score.
In 2013, he was recruited to Stanford University to lead the Division of Gastroenterology and Hepatology. Under his leadership, the Division prospered with a significant growth in the breadth and depth of faculty and their expertise, innovative educational programs for the GI, liver and other advanced fellowships, excellence in scientific scholarship and supportive community with emphasis on mentorship and individual growth.
After serving as the GI Chief at Stanford for nearly 11 years, he is returning to Mayo to create the Center for Policy and Outcomes Research in Transplantation (CPORT) based in the Arizona campus.
